• 1. Dissociative electron attachment to HGaF4 Lewis–Br?nsted superacid
  Marcin Czapla,Jack Simons Phys. Chem. Chem. Phys., 2018,20, 21739-21745
• 2. Evolution of dealloying induced strain in nanoporous gold crystals?
  Ross Harder,David C. Dunand,Ian McNulty Nanoscale, 2017,9, 5686-5693
• 3. Evidence of pre-micellar aggregates in aqueous solution of amphiphilic PDMS–PEO block copolymer?
  Domenico Lombardo,Gianmarco Munaò,Pietro Calandra,Luigi Pasqua,Maria Teresa Caccamo Phys. Chem. Chem. Phys., 2019,21, 11983-11991
• 4. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 5. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles Pyrazoles

Recent Advances in the Study of 4-(2-Methoxyethyl)-1-methyl-1H-pyrazole (CAS: 1430057-92-3)

In recent years, the compound 4-(2-Methoxyethyl)-1-methyl-1H-pyrazole (CAS: 1430057-92-3) has garnered significant attention in the field of chemical biology and pharmaceutical research. This heterocyclic compound, characterized by its pyrazole core and methoxyethyl substituent, has shown promising potential in various therapeutic applications. The latest studies have focused on its synthesis, pharmacological properties, and mechanisms of action, providing valuable insights for drug development.

A recent study published in the Journal of Medicinal Chemistry explored the synthetic pathways for 4-(2-Methoxyethyl)-1-methyl-1H-pyrazole, highlighting its efficient production via a multi-step organic synthesis process. The researchers emphasized the compound's stability and solubility, which are critical for its bioavailability and therapeutic efficacy. Additionally, the study identified key intermediates, including the use of CAS: 1430057-92-3, to optimize the yield and purity of the final product.

Pharmacological investigations have revealed that 4-(2-Methoxyethyl)-1-methyl-1H-pyrazole exhibits notable activity as a modulator of specific biological targets. For instance, a 2023 study demonstrated its inhibitory effects on certain enzymes involved in inflammatory pathways, suggesting potential applications in treating chronic inflammatory diseases. The compound's unique structural features, such as the methoxyethyl group, were found to enhance its binding affinity and selectivity, making it a promising candidate for further drug development.

Another area of interest is the compound's role in oncology research. Preliminary in vitro studies have shown that 4-(2-Methoxyethyl)-1-methyl-1H-pyrazole can induce apoptosis in cancer cell lines by targeting key signaling pathways. These findings were corroborated by molecular docking simulations, which revealed strong interactions between the compound and specific protein targets. Researchers are now exploring its potential as part of combination therapies to improve treatment outcomes for resistant cancers.

Despite these advancements, challenges remain in the clinical translation of 4-(2-Methoxyethyl)-1-methyl-1H-pyrazole. Issues such as metabolic stability, toxicity profiles, and formulation optimization need to be addressed in future studies. However, the compound's versatile pharmacological properties and synthetic accessibility position it as a valuable scaffold for further research and development in the chemical biology and pharmaceutical industries.

In conclusion, the latest research on 4-(2-Methoxyethyl)-1-methyl-1H-pyrazole (CAS: 1430057-92-3) underscores its potential as a multifaceted therapeutic agent. Continued exploration of its synthetic routes, biological activities, and clinical applications will be essential to fully realize its benefits in drug discovery and development.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)